{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":true},"limitationsAndCaveats":{"description":"On 13 March 2024, enrolment to the T-DXd-alone arm was prematurely closed following the recommendation of the Independent Data Monitoring Committee (IDMC). Patients already receiving T-DXd alone could continue treatment until completion of eight cycles, meeting any discontinuation criteria, or switching to the investigator's choice of local SOC-classified as having a non-pCR."},"pointOfContact":{"email":"information.center@astrazeneca.com","organization":"AstraZeneca Clinical Study Information Center","phone":"1-877-240-9479","title":"Global Clinical Lead"}}